17 results on '"N. Abdel"'
Search Results
2. P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
3. EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis
4. EP1.01-23 SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness
5. P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
6. EP1.01-23 SRC Inhibition with Bosutinib as a Potential Approach for Restoring Pemetrexed Responsiveness
7. P1.01-64 Predictive Value of K-Ras Subset Mutations and PD-L1 in Pulmonary Sarcomatoid Carcinoma (PSC)
8. EP1.01-67 Molecular Profiling of K-Ras and Its Subtypes in NSCLC Patients with Liver Metastasis
9. P1.04-60 Impact of Metastatic Location on Survival in Stage-IV Non-Small Cell Lung Cancer (NSCLC) Treated with Immunotherapy
10. P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
11. PS06.06 Immune Checkpoint Markers in Lung Large Cell Neuroendocrine Carcinomas (L- LCNEC)
12. PS02.10 Pneumonitis as a Complication of anti-PD/PDL1 Immunotherapy: A Meta-Analysis of Randomized Clinical Trials
13. P2.01-015 Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel–Based Therapy
14. P2.01-015 Longitudinal Assessment of Performance Status (PS) in Patients with NSCLC and ECOG PS 2 on Nab-Paclitaxel–Based Therapy
15. P2.01-014 ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel–Based Therapy in Patients with NSCLC and ECOG PS 2
16. P2.01-014 ABOUND.PS2: Safety and Efficacy of Nab-Paclitaxel–Based Therapy in Patients with NSCLC and ECOG PS 2
17. PS02.11 Is There any Cardiotoxicity with Anti-PD/PDL 1 Immunotherapy? A Meta-Analysis of Randomized Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.